Ruijian Medicine Secures 210M RMB in C1 Funding

Post LinkedIn

🔥Read original on 36氪

#biotech#ai-healthcare#fundingruijian-medicine-ai+-platformruijian-medicineai-drug-discovery

💡Example of AI-driven biotechnology scaling through specialized chemical induction platforms.

⚡ 30-Second TL;DR

What Changed

Raised 210 million RMB in C1 round

Why It Matters

The integration of AI into chemical induction platforms signifies a growing trend in AI-driven drug discovery and precision medicine.

What To Do Next

Investigate how AI-driven chemical induction models are being applied to accelerate drug discovery pipelines.

Who should care:Researchers & Academics

Key Points

•Raised 210 million RMB in C1 round
•Focus on AI+ chemical induction platform upgrades
•Expansion of global clinical development and production capacity

🧠 Deep Insight

Background and context from public sources — not the original article. 7 sources cited.

🔑 Enhanced Key Takeaways

•Ruijian Medicine, founded in 2017, specializes in developing cell therapies primarily for neurological and ophthalmological diseases, utilizing its proprietary chemical induction technology.
•The company's lead candidate, NouvNeu001, an iPSC-derived drug targeting Parkinson's disease, received implicit approval for clinical trials in China in August 2023, marking it as the world's first universal cell therapy product based on chemical induction to enter clinical stages for this indication.
•Prior to the C1 round, Ruijian Medicine had secured approximately $40 million in total funding across four rounds, including a nearly 100 million RMB A+ round in January 2022 led by Changjiang Securities innovation investment, and a Series B round in September 2025.
•Co-leading the C1 funding round, Xingze Capital is a significant investor in the life sciences sector, established in 2015, and manages six RMB funds with a total asset management amount of nearly 6.5 billion RMB.

🔮 Future ImplicationsAI analysis grounded in cited sources

Ruijian Medicine's AI-driven chemical induction platform could significantly accelerate the development and accessibility of universal cell therapies.

By leveraging AI, the company aims to streamline the complex process of chemically inducing functional cells, potentially reducing development timelines and costs for cell-based treatments.

China is poised to become a global leader in AI-driven regenerative medicine and cell therapy.

Substantial national funding, supportive regulatory reforms, and the emergence of innovative companies like Ruijian Medicine, alongside advanced AI drug screening platforms, indicate a strong national commitment and capability in this sector.

⏳ Timeline

2017

Wuhan Ruijian Pharmaceutical Technology (Ruijian Medicine) founded.

2019-01

Secured its first funding round.

2022-01

Completed nearly 100 million RMB A+ round of financing led by Changjiang Securities innovation investment.

2023-08-02

NouvNeu001, an iPSC-derived drug for Parkinson's disease, received implicit approval for a new drug clinical trial, becoming the world's first chemical induction-based universal cell therapy for Parkinson's to enter clinical stage.

2023-09-16

Drug clinical trial application for Human Dopaminergic Precursor Cell Injection (IPSC-derived drug) accepted for a second indication.

2025-09-04

Completed a Series B funding round, contributing to a total of $40 million raised across four rounds.

📎 Sources (7)

Factual claims are grounded in the sources below. Forward-looking analysis is AI-generated interpretation.

🔥Read original article on 36氪

📰

Weekly AI Recap

Read this week's curated digest of top AI events →

👉Related Updates

Same topic

Explore #biotech

Same product